leu-ser-lys-leu-peptide and Proteinuria

leu-ser-lys-leu-peptide has been researched along with Proteinuria* in 2 studies

Other Studies

2 other study(ies) available for leu-ser-lys-leu-peptide and Proteinuria

ArticleYear
Blockade of TSP1-dependent TGF-β activity reduces renal injury and proteinuria in a murine model of diabetic nephropathy.
    The American journal of pathology, 2011, Volume: 178, Issue:6

    Transforming growth factor-β (TGF-β) is key in the pathogenesis of diabetic nephropathy. Thrombospondin 1 (TSP1) expression is increased in diabetes, and TSP1 regulates latent TGF-β activation in vitro and in diabetic animal models. Herein, we investigate the effect of blockade of TSP1-dependent TGF-β activation on progression of renal disease in a mouse model of type 1 diabetes (C57BL/6J-Ins2(Akita)) as a targeted treatment for diabetic nephropathy. Akita and control C57BL/6 mice who underwent uninephrectomy received 15 weeks of thrice-weekly i.p. treatment with 3 or 30 mg/kg LSKL peptide, control SLLK peptide, or saline. The effects of systemic LSKL peptide on dermal wound healing was assessed in type 2 diabetic mice (db/db). Proteinuria (urinary albumin level and albumin/creatinine ratio) was significantly improved in Akita mice treated with 30 mg/kg LSKL peptide. LSKL treatment reduced urinary TGF-β activity and renal phospho-Smad2/3 levels and improved markers of tubulointerstitial injury (fibronectin) and podocytes (nephrin). However, LSKL did not alter glomerulosclerosis or glomerular structure. LSKL did not increase tumor incidence or inflammation or impair diabetic wound healing. These data suggest that selective targeting of excessive TGF-β activity through blockade of TSP1-dependent TGF-β activation represents a therapeutic strategy for treating diabetic nephropathy that preserves the homeostatic functions of TGF-β.

    Topics: Albuminuria; Amino Acid Sequence; Animals; Creatinine; Dermis; Diabetic Nephropathies; Disease Models, Animal; Fibronectins; Inflammation; Injections, Intraperitoneal; Kidney; Mice; Mice, Inbred C57BL; Molecular Sequence Data; Peptides; Phosphorylation; Proteinuria; Signal Transduction; Smad2 Protein; Thrombospondin 1; Transforming Growth Factor beta; Wound Healing

2011
Thrombospondin-1 is a major activator of TGF-beta in fibrotic renal disease in the rat in vivo.
    Kidney international, 2004, Volume: 65, Issue:2

    Transforming growth factor-beta (TGF-beta), a profibrotic cytokine involved in many scarring processes, has to be activated extracellularly before it can bind to its receptors. Thrombospondin 1 (TSP1), a multifunctional matricellular glycoprotein, has been identified as an activator of TGF-beta in in vitro systems and during mouse postnatal development in vivo. TSP1 is expressed de novo in many inflammatory disease processes, including glomerular disease.. In this study we investigated whether peptides specifically interfering with the activation process of TGF-beta by TSP1 may be able to block activation of TGF-beta in an in vivo model of mesangial proliferative glomerulonephritis.. Continuous intravenous infusion of blocking peptide by minipumps significantly reduced expression of active TGF-beta in glomeruli on day 7 of disease as indicated by immunohistochemistry, bioassay, and activation of the TGF-beta signal transduction pathway, while total TGF-beta expression was unchanged. Inhibition of glomerular TGF-beta activation was accompanied by a decrease of glomerular extracellular matrix accumulation and proteinuria, but was without effect on mesangial cell proliferation or influx of monocytes/macrophages.. TSP1 is a major endogenous activator of TGF-beta in experimental inflammatory glomerular disease. Drugs interfering with the activation of TGF-beta by locally produced TSP1 may be considered as a future specific treatment of scarring kidney disease.

    Topics: Animals; Cell Division; Extracellular Matrix; Fibrosis; Glomerular Mesangium; Glomerulonephritis; Isoantibodies; Macrophages; Peptides; Proteinuria; Rats; Rats, Sprague-Dawley; Receptors, Transforming Growth Factor beta; Thrombospondin 1; Transforming Growth Factor beta; Transforming Growth Factor beta1; Transforming Growth Factor beta2

2004